Department of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, China.
Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, China.
Medicine (Baltimore). 2024 Aug 30;103(35):e39403. doi: 10.1097/MD.0000000000039403.
To evaluate the efficacy and safety of rectal chloral hydrate (CH) in pediatric procedural sedation.
Seven electronic databases and 3 clinical trials registry platforms were searched, and the deadline was August 2022. Randomized controlled trials evaluating the efficacy and safety of rectal CH in pediatric procedural sedation were included by 2 reviewers. The extracted outcomes included the success rate of sedation, sedation latency, sedation duration, and adverse events. The Cochrane risk of bias tool was used to assess the risk of bias. The outcomes were analyzed using Review Manager 5.3 software.
Forty-four randomized controlled trials with 8007 children were included in the meta-analysis. The success rate of sedation in the rectal CH group was significantly higher than that in the placebo group (risk ratio [RR], 2.60 [95% confidence interval [CI], 1.74-3.89]; P < .01; RR, 1.24 [95% CI, 1.01-1.54]; P = .04), oral CH group (RR, 1.12 [95% CI, 1.09-1.14]; I2 = 36%; P < .001; number needed to treat [NNT] = 10), diazepam group (RR, 1.21 [95% CI, 1.10-1.33]; I2 = 0%; P < .001; NNT = 6), phenobarbital group (RR, 1.24 [95% CI, 1.13-1.35]; I2 = 12%; P < .001; NNT = 6), and ketamine group (RR, 1.39 [95% CI, 1.20-1.60]; I2 = 20%; P < .001; NNT = 5). There was no significant difference in the success rate of sedation between the rectal CH group and the midazolam group (RR, 0.98 [95% CI, 0.86-1.11]; I2 = 51%; P > .05). The sedation latency was significantly shorter in rectal CH group than that in the oral CH group (mean difference [MD], -6.36 [95% CI, -7.04 to -5.68]; I2 = 49%; P < .001) and the phenobarbital group (MD, -7.64 [95% CI, -9.12 to -6.16]; P < .00001). The sedation duration in the rectal CH group was significantly longer than in the oral CH group (MD, 6.43 [95% CI, 4.39-8.47]; I2 = 0%; P < .001). The overall incidence of adverse events was significantly lower with rectal CH than with oral CH (RR, 0.21 [95% CI, 0.16-0.29]; I2 = 45%; P < .001) and ketamine (RR, 0.26 [95% CI, 0.12-0.60]; I2 = 0%; P = .001). There was no significant difference in the overall incidence of adverse events with rectal CH compared with intramuscular midazolam (RR, 0.55 [95% CI, 0.23-1.28]; P = .17) and intranasal midazolam (RR, 3.00 [95% CI, 0.66-13.69]; P = .16).
The available evidence suggests that rectal CH cloud be an effective and safe sedative agent for pediatric procedural sedation.
评估直肠氯醛(CH)在儿科程序镇静中的疗效和安全性。
检索了七个电子数据库和三个临床试验注册平台,截止日期为 2022 年 8 月。通过两位评审员纳入评价直肠 CH 在儿科程序镇静中疗效和安全性的随机对照试验。提取的结局包括镇静成功率、镇静潜伏期、镇静持续时间和不良事件。使用 Cochrane 偏倚风险工具评估偏倚风险。使用 Review Manager 5.3 软件分析结果。
纳入 44 项随机对照试验,共 8007 名儿童。直肠 CH 组的镇静成功率显著高于安慰剂组(风险比 [RR],2.60 [95%置信区间 [CI],1.74-3.89];P<0.01;RR,1.24 [95% CI,1.01-1.54];P=0.04)、口服 CH 组(RR,1.12 [95% CI,1.09-1.14];I²=36%;P<0.001;需要治疗人数 [NNT] = 10)、地西泮组(RR,1.21 [95% CI,1.10-1.33];I²=0%;P<0.001;NNT=6)、苯巴比妥组(RR,1.24 [95% CI,1.13-1.35];I²=12%;P<0.001;NNT=6)和氯胺酮组(RR,1.39 [95% CI,1.20-1.60];I²=20%;P<0.001;NNT=5)。直肠 CH 组与咪达唑仑组的镇静成功率无显著差异(RR,0.98 [95% CI,0.86-1.11];I²=51%;P>0.05)。直肠 CH 组的镇静潜伏期明显短于口服 CH 组(平均差值 [MD],-6.36 [95% CI,-7.04 至-5.68];I²=49%;P<0.001)和苯巴比妥组(MD,-7.64 [95% CI,-9.12 至-6.16];P<0.00001)。直肠 CH 组的镇静持续时间明显长于口服 CH 组(MD,6.43 [95% CI,4.39-8.47];I²=0%;P<0.001)。直肠 CH 组的不良事件总发生率明显低于口服 CH 组(RR,0.21 [95% CI,0.16-0.29];I²=45%;P<0.001)和氯胺酮组(RR,0.26 [95% CI,0.12-0.60];I²=0%;P=0.001)。与肌内注射咪达唑仑(RR,0.55 [95% CI,0.23-1.28];P=0.17)和鼻内咪达唑仑(RR,3.00 [95% CI,0.66-13.69];P=0.16)相比,直肠 CH 组的不良事件总发生率无显著差异。
现有证据表明,直肠 CH 可能是儿科程序镇静的一种有效且安全的镇静剂。